CHRS · NASDAQ · Biotechnology

Coherus Oncology (CHRS)

Commercializes LOQTORZI while advancing mid-stage immuno-oncology antibodies.

$1.31
After hours+0.01 (+0.77%)
At close$1.30(−5.11%)